Proteins and nucleic acids encoding same

A method for determining the presence of or predisposition to a disease associated with altered levels of SEC1 in a first mammalian subject, said method comprising:

• (a) providing a protein sample from said first mammalian subject;
• (b) providing a control protein sample from a second mammalian subject known not to have or be predisposed to said disease;
• (c) measuring the amount of SEC1 polypeptide in said subject sample;
• and
• (d) comparing the amount of SEC1 polypeptide in said subject protein sample to the amount of SEC1 polypeptide in said control protein sample,
• wherein an alteration in the expression level of the SEC1 polypeptide in the first subject sample as compared to the control sample indicates the presence or predisposition to said disease.

A method for determining the presence of or predisposition to a disease associated with altered levels of the nucleic acid of SEC1 in a first mammalian subject, said method comprising:

• (a) providing a nucleic acid sample from said first mammalian subject;
• (b) providing a control nucleic acid sample from a second mammalian subject known not to have or be predisposed to said disease;
• (c) measuring the amount of SEC1 nucleic acid in said subject sample;
• and
• (d) comparing the amount of SEC1 nucleic acid in said subject nucleic acid sample to the amount of SEC1 nucleic acid in said control nucleic acid sample,
• wherein an alteration in the expression level of the SEC1 nucleic acid in the first subject sample as compared to the control sample indicates the presence or predisposition to said disease.

A method for determining the presence of or predisposition to a disease associated with altered levels of SEC1, SEC2, SEC3, SEC4, SEC5, SEC6, SEC7, SEC8, SEC9, SEC10, SEC11, or SEC12 in a first mammalian subject, said method comprising

• (a) Providing a sample from said first mammalian subject;
• (b) Providing a control sample from a second mammalian subject known not to have or be predisposed to said disease;
• (c) Measuring the amount of SEC1, SEC2, SEC3, SEC4, SEC5, SEC6, SEC7, SEC8, SEC9, SEC10, SEC11, or SEC12 in said subject sample;
• and
• (d) Comparing the amount of SEC1, SEC2, SEC3, SEC4, SEC5, SEC6, SEC7, SEC8, SEC9, SEC10, SEC11, or SEC12 in said subject protein sample to the amount of SEC1, SEC2, SEC3, SEC4, SEC5, SEC6, SEC7, SEC8, SEC9, SEC10, SEC11, or SEC12 in said control sample,
• wherein an alteration in the expression level of the SEC1, SEC2, SEC3, SEC4, SEC5, SEC6, SEC7, SEC8, SEC9, SEC10, SEC11, or SEC12 in the first subject sample as compared to the control sample indicates the presence or predisposition to said disease.

An isolated polypeptide comprising an amino acid sequence selected from the group consisting of:

• (a) a mature form of an amino acid sequence selected from the group consisting of SEQ ID NOS:26, 28, 30, 32, 34, 36, 38, 40 and 320;
• (b) a variant of a mature form of an amino acid sequence selected from the group consisting of SEQ ID NOS:26, 28, 30, 32, 34, 36, 38, 40 and 320, wherein one or more amino acid residues in said variant differs from the amino acid sequence of said mature form, provided that said variant differs in no more than 15% of the amino acid residues from the amino acid sequence of said mature form;
• (c) an amino acid sequence selected from the group consisting SEQ ID NOS:26, 28, 30, 32, 34, 36, 38, 40 and 320;
• and,
• (d) a variant of an amino acid sequence selected from the group consisting of SEQ ID NOS:26, 28, 30, 32, 34, 36, 38, 40 and 320, wherein one or more amino acid residues in said variant differs from the amino acid sequence of said mature form, provided that said variant differs in no more than 15% of amino acid residues from said amino acid sequence.

An isolated nucleic acid molecule comprising a nucleic acid sequence encoding a polypeptide comprising an amino acid sequence selected from the group consisting of:

• (a) a mature form of an amino acid sequence selected from the group consisting of SEQ ID NOS:26, 28, 30, 32, 34, 36, 38, 40 and 320;
• (b) a variant of a mature form of an amino acid sequence selected from the group consisting of SEQ ID NOS:26, 28, 30, 32, 34, 36, 38, 40 and 320, wherein one or more amino acid residues in said variant differs from the amino acid sequence of said mature form, provided that said variant differs in no more than 15% of the amino acid residues from the amino acid sequence of said mature form;
• (c) an amino acid sequence selected from the group consisting of SEQ ID NOS:26, 28, 30, 32, 34, 36, 38, 40 and 320;
• (d) a variant of an amino acid sequence selected from the group consisting SEQ ID NOS:26, 28, 30, 32, 34, 36, 38, 40 and 320, wherein one or more amino acid residues in said variant differs from the amino acid sequence of said mature form, provided that said variant differs in no more than 15% of amino acid residues from said amino acid sequence;
• (e) a nucleic acid fragment encoding at least a portion of a polypeptide comprising an amino acid sequence chosen from the group consisting of SEQ ID NOS:26, 28, 30, 32, 34, 36, 38, 40 and 320, or a variant of said polypeptide, wherein one or more amino acid residues in said variant differs from the amino acid sequence of said mature form, provided that said variant differs in no more than 15% of amino acid residues from said amino acid sequence;
• and
• (f) a nucleic acid molecule comprising the complement of (a), (b), (c), (d) or (e).